Blueprint Medicines Corporation (BPMC)
Largest Insider Buys in Sector
BPMC Stock Price History Chart
BPMC Stock Performance
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing …
Insider Activity of Blueprint Medicines Corporation
Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $38.44M worth of Blueprint Medicines Corporation stock.
On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $349,105 and sold $21.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.
List of Insider Buy and Sell Transactions, Blueprint Medicines Corporation
| 2024-10-03 | Sale | PRESIDENT, R & D | 3,633 0.0058% | $89.32 | $324,500 | +0.61% | ||
| 2024-09-09 | Sale | director | 19,702 0.0308% | $85.57 | $1.69M | +2.61% | ||
| 2024-08-15 | Sale | CHIEF FINANCIAL OFFICER | 4,409 0.0071% | $95.23 | $419,869 | 0.00% | ||
| 2024-08-05 | Sale | CHIEF COMMERCIAL OFFICER | 41,913 0.0663% | $93.19 | $3.91M | -3.13% | ||
| 2024-07-05 | Sale | CHIEF PEOPLE OFFICER | 3,850 0.0066% | $111.20 | $428,120 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF PEOPLE OFFICER | 8,817 0.0151% | $111.29 | $981,244 | 0.00% | ||
| 2024-06-28 | Sale | CHIEF PEOPLE OFFICER | 333 0.0006% | $111.15 | $37,013 | 0.00% | ||
| 2024-06-21 | Sale | CHIEF PEOPLE OFFICER | 74,034 0.1169% | $104.19 | $7.71M | -12.04% | ||
| 2024-06-05 | Sale | CHIEF SCIENTIFIC OFFICER | 4,000 0.0063% | $105.13 | $420,520 | -12.41% | ||
| 2024-06-04 | Sale | CHIEF MEDICAL OFFICER | 2,424 0.004% | $104.91 | $254,302 | -8.98% | ||
| 2024-06-03 | Sale | CHIEF SCIENTIFIC OFFICER | 2,436 0.0039% | $106.43 | $259,263 | -11.62% | ||
| 2024-06-03 | Sale | CHIEF MEDICAL OFFICER | 4,922 0.008% | $106.43 | $523,848 | -11.62% | ||
| 2024-05-31 | Sale | CHIEF MEDICAL OFFICER | 34,108 0.0547% | $105.91 | $3.61M | -12.14% | ||
| 2024-05-15 | Sale | CHIEF FINANCIAL OFFICER | 3,850 0.0062% | $106.95 | $411,772 | -12.26% | ||
| 2024-05-15 | Sale | PRINCIPAL ACCOUNTING OFFICER | 5,856 0.0094% | $106.96 | $626,379 | -12.26% | ||
| 2024-05-02 | Sale | CHIEF FINANCIAL OFFICER | 10,000 0.016% | $105.00 | $1.05M | -11.14% | ||
| 2024-05-02 | Sale | PRINCIPAL ACCOUNTING OFFICER | 1,834 0.0029% | $103.88 | $190,516 | -11.14% | ||
| 2024-03-28 | Sale | CHIEF FINANCIAL OFFICER | 5,000 0.0082% | $95.00 | $475,000 | -1.86% | ||
| 2024-03-20 | Sale | director | 25,073 0.0405% | $87.28 | $2.19M | +5.28% | ||
| 2024-03-15 | Sale | CHIEF FINANCIAL OFFICER | 13,734 0.0218% | $87.78 | $1.21M | +2.61% |
Insider Historical Profitability
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 153177 0.2411% | $99.46 | 1 | 26 | +10.84% |
| FMR LLC | 264898 0.417% | $99.46 | 1 | 9 | +9.46% | |
| Goldberg Mark Alan | 10812 0.017% | $99.46 | 1 | 6 | <0.0001% | |
| Demetri George | 5822 0.0092% | $99.46 | 1 | 9 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $611.61M | 10.3 | 6.45M | -2.08% | -$12.97M | 0.01 | |
| The Vanguard Group | $598.56M | 10.08 | 6.31M | +3.19% | +$18.5M | 0.01 | |
| T. Rowe Price | $592.95M | 9.98 | 6.25M | +15.14% | +$77.96M | 0.07 | |
| Fidelity Investments | $490.38M | 8.26 | 5.17M | +18.89% | +$77.9M | 0.03 | |
| Wellington Management Company | $396.05M | 6.67 | 4.18M | -2.37% | -$9.6M | 0.07 |